Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

OpenAI CEO Sam Altman surprised the tech world on Thursday with the launch of Operator, his company’s first AI agent that can ...

We saw several innovative uses of AI in the past week, and a bad slip-up in news sharing. A quick round-up: ...

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...

OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by ...

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in funding to support its research. The Financial Times today cited sources as ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

The pandemic saw a flurry of investment in biotech startups but the past three years have seen shrinking investments in the ...

The groundbreaking partnership focuses on leveraging AI to unlock advancements in cellular regeneration and anti-ageing ...

$540 $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025. Then $75 per month. Complete digital access to ...

OpenAI is venturing into the field of longevity science with an artificial intelligence model designed to optimize the ...